Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2026 08:30 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.Through its global access to medicines...
29. April 2026 07:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S. dollars year-over-year (YoY), and decreased by 3% in local...
29. April 2026 06:30 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track...
15. April 2026 08:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that...
14. April 2026 08:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

SANTA BARBARA, Calif. and PARSIPPANY, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics (NAFC) today announced...
30. März 2026 08:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...
30. März 2026 08:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...
30. März 2026 08:00 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
19. März 2026 16:30 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva Releases Q1 2026 Aide Memoire

TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on...
19. März 2026 16:30 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first...

Nächste Seite